A neural network approach to multi-biomarker panel discovery by high-throughput plasma proteomics profiling of breast cancer

Abstract

BackgroundIn the past several years, there has been increasing interest and enthusiasm in molecular biomarkers as tools for early detection of cancer. Liquid chromatography tandem mass spectrometry (LC/MS/MS) based plasma proteomics profiling technique is a promising technology platform to study candidate protein biomarkers for early detection of cancer. Factors such as inherent variability, protein detectability limitation, and peptide discovery biases among LC/MS/MS platforms have made the classification and prediction of proteomics profiles challenging. Developing proteomics data analysis methods to identify multi-protein biomarker panels for breast cancer diagnosis based on neural networks provides hope for improving both the sensitivity and the specificity of candidate cancer biomarkers for early detection.ResultsIn our previous method, we developed a Feed Forward Neural Network-based method to build the classifier for plasma samples of breast cancer and then applied the classifier to predict blind dataset of breast cancer. However, the optimal combination C* in our previous method was actually determined by applying the trained FFNN on the testing set with the combination. Therefore, in this paper, we applied a three way data split to the Feed Forward Neural Network for training, validation and testing based. We found that the prediction performance of the FFNN model based on the three way data split outperforms our previous method and the prediction performance is improved from (AUC = 0.8706, precision = 82.5%, accuracy = 82.5%, sensitivity = 82.5%, specificity = 82.5% for the testing set) to (AUC = 0.895, precision = 86.84%, accuracy = 85%, sensitivity = 82.5%, specificity = 87.5% for the testing set).ConclusionsFurther pathway analysis showed that the top three five-marker panels are associated with complement and coagulation cascades, signaling, activation, and hemostasis, which are consistent with previous findings. We believe the new approach is a better solution for multi-biomarker panel discovery and it can be applied to other clinical proteomics.

A novel strategy to identify autoantigens by proteomic analysis of plasma IgG-bound proteins

“…Identification of proteins in biological samples is a central focus of proteomics. The discovery and validation of biomarkers may be accomplished by mass spectrometry-based proteomics 19,20) , but in analyses of mass-limited samples like human plasma, it can be challenging to obtain sufficient enrichment of proteins to generate high-quality mass spectra. In the current analysis, we used three distinct processing methods to extract human plasma prior to LC-MS/ MS analysis.…”

Proteomics and phosphoproteomics in precision medicine: applications and challenges

“…More sophisticated methods such as machine learning and network-based approaches are also used. Machine learning methods such as support vector machine [63, 64] (SVM), neural networks [65–69], decision tree [67], random forest [70, 71] and genetic algorithms [72] have been successfully applied to proteomics data to identify biomarkers for several cancer types, heart failure and other conditions. Ahn et al [73] constructed a 29-plex array platform comprising 29 potential biomarkers associated with gastric adenocarcinoma.…”

Applying computation biology and “big data” to develop multiplex diagnostics for complex chronic diseases such as osteoarthritis

“…Although high-throughput “omics” platforms coupled with the application of complex bioinformatics approaches have had a number of successes in identifying potential biomarkers in complex diseases such as cancer (Wang et al, 2009 ; Zhang et al, 2013 ), sepsis (Lukaszewski et al, 2008 ), arthritis (Heard et al, 2014 ; Swan et al, 2013 ) and others, it is important to realize that some, if not all complex diseases have numerous associated co-morbidities and risk factors. Therefore, it is essential to have extremely well-characterized patient cohorts to be sure we are not identifying biomarkers associated with those co-morbidities and/or risk factors.…”